Rapport Therapeutics (RAPP) Accumulated Depreciation (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Accumulated Depreciation of $1.9 million for Q1 2026, up 59.5% year-over-year from $1.2 million in Q1 2025, and down 2.62% quarter-over-quarter from $2.0 million in Q4 2025.
Rapport Therapeutics (RAPP) Accumulated Depreciation (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Accumulated Depreciation for 4 consecutive years, with $1.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Depreciation rose 59.5% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (up 59.5% YoY), while the FY2025 annual figure was $2.0 million, up 105.39% from the prior year.
- Accumulated Depreciation eased to $1.9 million in Q1 2026 per RAPP's latest filing, from $2.0 million in the prior quarter.
- Across five years, Accumulated Depreciation topped out at $2.0 million in Q4 2025 and bottomed at $127000.0 in Q4 2023.
- Historically, Accumulated Depreciation has averaged $1.2 million across 4 years, with a median of $1.2 million in 2025.
- Annual changes were most pronounced in 2024 — Accumulated Depreciation jumped 659.84% — and 2026, when it jumped 59.5%.
- Rapport Therapeutics' Accumulated Depreciation stood at $127000.0 in 2023, then surged by 659.84% to $965000.0 in 2024, then soared by 105.39% to $2.0 million in 2025, then retreated by 2.62% to $1.9 million in 2026.
- Business Quant data shows RAPP's Accumulated Depreciation at $1.9 million in Q1 2026, $2.0 million in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.14 Mn |
| Mar 31, 2026 | 1.93 Mn |
| Dec 31, 2025 | 1.98 Mn |
| Sep 30, 2025 | 1.72 Mn |
| Jun 30, 2025 | 1.46 Mn |
| Mar 31, 2025 | 1.21 Mn |
| Dec 31, 2024 | 965,000.00 |
| Sep 30, 2024 | 705,000.00 |
| Jun 30, 2024 | 485,000.00 |
| Dec 31, 2023 | 127,000.00 |